Xenetic Biosciences, Inc.

Equities

XBIO

US9840156023

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 01/06/2024 am IST			5-day change	1st Jan Change
3.9 ^USD	+4.28%		+0.03%	+13.04%

22/05	Xenetic Biosciences, Inc. Announces Management Resignations	CI
22/05	Xenetic Biosciences, Inc. Announces Chief Executive Officer Changes	CI

Xenetic Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020

March 17, 2021 at 02:43 am IST

Xenetic Biosciences, Inc. announced earnings results for the full year ended December 31, 2020. For the full year, the company announced total revenue was USD 436,942 compared to USD 17,066 a year ago. Operating loss was USD 13.937 million compared to USD 12.886 million a year ago. Net loss was USD 10.893 million compared to USD 12.775 million a year ago. Basic loss per share from continuing operations was USD 1.7 compared to USD 6.33 a year ago.

Latest news about Xenetic Biosciences, Inc.

Xenetic Biosciences, Inc. Announces Management Resignations	23/05	CI
Xenetic Biosciences, Inc. Announces Chief Executive Officer Changes	23/05	CI
Xenetic Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05	CI
Xenetic Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	22/03	CI
CLS Therapeutics Discloses its Views on Xenetic Biosciences	18/03	CI
Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of Its DNase-Based Oncology Platform	17/01	CI
Xenetic Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11	CI
Xenetic Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/23/11	CI
North American Morning Briefing : Debt-Ceiling -2-	17/23/17	DJ
HC Wainwright Downgrades Xenetic Biosciences to Neutral From Buy	16/23/16	MT
Xenetic Biosciences to Implement 1-for-10 Reverse Split	13/23/13	MT
Xenetic Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/23/12	CI
Xenetic Biosciences, The Scripps Research Institute Enter Into Research Collaboration	11/23/11	MT
Xenetic Biosciences, Inc. Announces the Appointment of Jonathan Spicer to its Scientific Advisory Board	16/22/16	CI
Xenetic Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	10/22/10	CI
Xenetic Biosciences, Inc. announced that it has received $0.488835 million in funding from CLS Therapeutics, LLC	13/22/13	CI
Xenetic Biosciences, Inc. announced that it expects to receive $0.488835 million in funding from CLS Therapeutics, LLC	12/22/12	CI
Xenetic Biosciences, Inc. Appoints Allan Tsung, to Its Scientific Advisory Board	04/22/04	CI
Xenetic Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	12/22/12	CI
Xenetic Biosciences, VolitionRx to Develop Adoptive Cell Therapies to Treat Cancer	02/22/02	MT
Xenetic Biosciences Signs Manufacturing Deal With Catalent Unit for Cancer Platform	07/22/07	MT
Xenetic Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	13/22/13	CI
Xenetic Biosciences, Inc. announced that it has received $0.86625 million in funding	04/22/04	CI
HC Wainwright Adjusts Price Target on Xenetic Biosciences to $4 From $5, Reiterates Buy Rating	02/22/02	MT
Xenetic Biosciences, Inc. Enters into Sublicense Agreement with CLS Therapeutics Ltd	27/22/27	CI

Chart Xenetic Biosciences, Inc.

Duration

Period

More charts

Company Profile

Xenetic Biosciences, Inc. is a biopharmaceutical company. The Company is focused on advancing immune-oncology technologies addressing hard to treat cancers. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. It is focused on advancing the development of its DNase platform toward a first-in-human, multicenter, dose escalation and dose-expansion study of IV rhDNase I in subjects with locally advanced or metastatic solid tumors. Its systemic DNase program is initially targeting multi-billion-dollar indications including pancreatic cancer, which includes pancreatic ductal adenocarcinoma (PDAC), colorectal carcinoma (CRC) and other gastrointestinal cancers. These are all cancer indications with significant unmet need, and with opportunities for substantial improvement of the available therapeutic options.

Sector

Biotechnology & Medical Research

Calendar

09/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Xenetic Biosciences, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

3.9

Average target price

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
XENETIC BIOSCIENCES, INC.	+13.04%	60.09L
VERTEX PHARMACEUTICALS INCORPORATED	+11.91%	12TCr
REGENERON PHARMACEUTICALS, INC.	+11.60%	11TCr
BIONTECH SE	-4.68%	2.43TCr
ARGENX SE	-0.82%	2.2TCr
GENMAB A/S	-10.12%	1.82TCr
WUXI APPTEC CO., LTD.	-42.12%	1.64TCr
BEIGENE, LTD.	-17.47%	1.56TCr
NEUROCRINE BIOSCIENCES, INC.	+2.77%	1.36TCr
SAREPTA THERAPEUTICS, INC.	+34.58%	1.23TCr

Bio Therapeutic Drugs